642 related articles for article (PubMed ID: 32335259)
1. Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.
Sussman CR; Wang X; Chebib FT; Torres VE
Cell Signal; 2020 Aug; 72():109649. PubMed ID: 32335259
[TBL] [Abstract][Full Text] [Related]
2. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
[TBL] [Abstract][Full Text] [Related]
3. The genetics and physiology of polycystic kidney disease.
Calvet JP; Grantham JJ
Semin Nephrol; 2001 Mar; 21(2):107-23. PubMed ID: 11245774
[TBL] [Abstract][Full Text] [Related]
4. Expanding the role of vasopressin antagonism in polycystic kidney diseases: From adults to children?
Janssens P; Weydert C; De Rechter S; Wissing KM; Liebau MC; Mekahli D
Pediatr Nephrol; 2018 Mar; 33(3):395-408. PubMed ID: 28455745
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.
Zhou X; Torres VE
Front Mol Biosci; 2022; 9():981963. PubMed ID: 36120538
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase 6 inhibition reduces cysts by decreasing cAMP and Ca
Yanda MK; Liu Q; Cebotaru V; Guggino WB; Cebotaru L
J Biol Chem; 2017 Oct; 292(43):17897-17908. PubMed ID: 28887310
[TBL] [Abstract][Full Text] [Related]
7. Multidrug therapy for polycystic kidney disease: a review and perspective.
Aguiari G; Catizone L; Del Senno L
Am J Nephrol; 2013; 37(2):175-82. PubMed ID: 23428809
[TBL] [Abstract][Full Text] [Related]
8. Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.
Torres VE; Harris PC
J Am Soc Nephrol; 2014 Jan; 25(1):18-32. PubMed ID: 24335972
[TBL] [Abstract][Full Text] [Related]
9. Calcium restores a normal proliferation phenotype in human polycystic kidney disease epithelial cells.
Yamaguchi T; Hempson SJ; Reif GA; Hedge AM; Wallace DP
J Am Soc Nephrol; 2006 Jan; 17(1):178-87. PubMed ID: 16319189
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic advances in ADPKD: the future awaits.
Capuano I; Buonanno P; Riccio E; Amicone M; Pisani A
J Nephrol; 2022 Mar; 35(2):397-415. PubMed ID: 34009558
[TBL] [Abstract][Full Text] [Related]
11. TGR5 contributes to hepatic cystogenesis in rodents with polycystic liver diseases through cyclic adenosine monophosphate/Gαs signaling.
Masyuk TV; Masyuk AI; Lorenzo Pisarello M; Howard BN; Huang BQ; Lee PY; Fung X; Sergienko E; Ardecky RJ; Chung TDY; Pinkerton AB; LaRusso NF
Hepatology; 2017 Oct; 66(4):1197-1218. PubMed ID: 28543567
[TBL] [Abstract][Full Text] [Related]
12. Therapies to slow polycystic kidney disease.
Torres VE
Nephron Exp Nephrol; 2004; 98(1):e1-7. PubMed ID: 15361692
[TBL] [Abstract][Full Text] [Related]
13. "ADPKD-omics": determinants of cyclic AMP levels in renal epithelial cells.
Mehta YR; Lewis SA; Leo KT; Chen L; Park E; Raghuram V; Chou CL; Yang CR; Kikuchi H; Khundmiri S; Poll BG; Knepper MA
Kidney Int; 2022 Jan; 101(1):47-62. PubMed ID: 34757121
[TBL] [Abstract][Full Text] [Related]
14. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease.
Devuyst O; Torres VE
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):459-70. PubMed ID: 23736843
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and mitochondria in polycystic kidney disease research and therapy.
Padovano V; Podrini C; Boletta A; Caplan MJ
Nat Rev Nephrol; 2018 Nov; 14(11):678-687. PubMed ID: 30120380
[TBL] [Abstract][Full Text] [Related]
16. Pre-clinical evaluation of dual targeting of the GPCRs CaSR and V2R as therapeutic strategy for autosomal dominant polycystic kidney disease.
Di Mise A; Wang X; Ye H; Pellegrini L; Torres VE; Valenti G
FASEB J; 2021 Oct; 35(10):e21874. PubMed ID: 34486176
[TBL] [Abstract][Full Text] [Related]
17. Adhesion GPCRs as a paradigm for understanding polycystin-1 G protein regulation.
Maser RL; Calvet JP
Cell Signal; 2020 Aug; 72():109637. PubMed ID: 32305667
[TBL] [Abstract][Full Text] [Related]
18. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
Olalekan K; Fox A; Gilbert R
Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
[TBL] [Abstract][Full Text] [Related]
19. Molecular and cellular pathogenesis of autosomal dominant polycystic kidney disease.
Bastos AP; Onuchic LF
Braz J Med Biol Res; 2011 Jul; 44(7):606-17. PubMed ID: 21625823
[TBL] [Abstract][Full Text] [Related]
20. Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells.
Belibi FA; Reif G; Wallace DP; Yamaguchi T; Olsen L; Li H; Helmkamp GM; Grantham JJ
Kidney Int; 2004 Sep; 66(3):964-73. PubMed ID: 15327388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
